Top

Inflammopharmacology

Published in:

01-02-2015 | Review

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

Authors: Waheed Asghar, Fakhreddin Jamali

Published in: Inflammopharmacology | Issue 1/2015

Abstract

Purpose

Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates.

Methods

We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90 days exposure) and/or vascular/renal outcomes (any exposure) after meloxicam use, published until April 2014. The combined odd ratio values (OR′; 95 % CI) were calculated using the random effect inverse variance model.

Results

We found 19 eligible studies out of 2,422 reports. Meloxicam demonstrated a low increase in composite risk (OR′ 1.14; CI 1.04–1.25) which was mainly vascular in nature (OR′ 1.35; CI 1.18–1.55] as it did not elevate myocardial (OR′ 1.13; CI 0.98–1.32) or renal (OR′, 0.99; CI 0.72–1.35) risks. Relative to meloxicam, other NSAIDs increased the composite risk, in a dose-dependent fashion, in the following order: rofecoxib > indomethacin > diclofenac > celecoxib > naproxen > ibuprofen. OR′ was also influenced by type of disease and the comparator used, and acetylsalicylic acid.

Conclusion

NSAIDs are heterogeneous in increasing CV/renal risks. The low increased risk associated with meloxicam is mainly vascular in origin.

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115(12):1634–1642PubMedCrossRef

Arvind C, Bichile L, Rajadhyaksha AG, Gadgil D, Maroli S, Goregaonkar AB, Dhaon BK (2004) Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: an Indian experience. APLAR J Rheum 7:108–116CrossRef

Balmaceda CM (2014) Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. BMC Musculoskelet Disord 15:27PubMedCentralPubMedCrossRef

Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769–779PubMedCrossRef

Biere-Rafi S, Di Nisio M, Gerdes V, Porreca E, Souverein P, Boer A et al (2011) Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 20(6):635–642PubMedCrossRef

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520–1528PubMedCrossRef

Brater DC, Harris C, Redfern JS, Gertz BJ (2001) Renal effects of COX-2-selective inhibitors. Am J Nephrol 21(1):1–15PubMedCrossRef

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102PubMedCrossRef

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99(3):132–140PubMedCentralPubMedCrossRef

Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS (2010) Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 41(9):1884–1890PubMedCrossRef

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. (2008). Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12(11):1–278

Davies NM, Jamali F (2004) COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 7(3):332–336PubMed

Davies NM, Longstreth J, Jamali F (2001) Misoprostol therapeutics revisited. Pharmacotherapy 21(1):60–73PubMedCrossRef

FDA’s Arthritis, Drug Safety and Risk Management Advisory Committee (2005) Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Available at: http://www.fda.gov/oc/advisory/accalendar/2005/cder12532ddd0216171805.html. Accessed 5 July 2014

FDA’s Arthritis, Drug Safety and Risk Management Advisory Committee (2014). Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting Announcement. Available at: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm380871.htm. Accessed 8 Apr 2014

Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85(2):190–197PubMedCrossRef

Fosslien E (2005) Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 35(4):347–385PubMed

Garcia Rodriguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52(20):1628–1636PubMedCrossRef

Gladding P, Webster M, Farrell H, Zeng I, Park R, Ruijne N (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101(7):1060–1063PubMedCrossRef

Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116(1):4–15PubMedCentralPubMedCrossRef

Harirforoosh S, Jamali F (2009) Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 8(6):669–681PubMedCrossRef

Harirforoosh S, Aghazadeh-Habashi A, Jamali F (2006) Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 33(10):917–924PubMedCrossRef

Harirforoosh S, Asghar W, Jamali F (2013) Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 16(5):821–847PubMed

Hartling L, Milne A, Hamm MP, Vandermeer B, Ansari M, Tsertsvadze A et al (2013) Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol 66(9):982–993PubMedCrossRef

Hassan MH, El-Beshbishy HA, Aly H, Attia SM, Bahashwan SA, Ghobara MM (2014) Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. Cancer Chemother Pharmacol 74(3):559–569PubMedCrossRef

Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE et al (2006) NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27(14):1657–1663PubMedCrossRef

Higgins J, Green S (2008) Cochrane handbook for systematic reviews of interventions. Chichester, Wiley, England

Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Sugioka T et al (2014) Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circ J 78(1):194–205PubMedCrossRef

Hosie J, Distel M, Bluhmki E (1996) Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 35(Suppl 1):39–43PubMedCrossRef

Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT (2006) Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 29(3):261–272PubMedCrossRef

Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA (2005) Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45(3):531–539PubMedCrossRef

Jamali F (2007). Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med 167(21): 2371–2372; author reply 2372

Jick SS (2000) The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy 20(7):741–744PubMedCrossRef

Jones SF, Power I (2005) Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Br J Anaesth 95(3):281–284PubMedCrossRef

Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364(9450):2021–2029PubMedCrossRef

Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-iflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332(7553):1302–1308PubMedCentralPubMedCrossRef

Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Lamberts M, Khalid U et al (2014) Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study. Circ Heart Fail 7(5):717–722PubMedCrossRef

Kuo D, Crowson CS, Gabriel SE, Matteson EL (2014) Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol 2014:523897PubMedCentralPubMedCrossRef

Lafrance JP, Miller DR (2012) Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis 60(1):82–89PubMedCrossRef

Lapeyre-Mestre M, Grolleau S, Montastruc JL (2013) Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol 27(2):223–230PubMedCrossRef

Layton D, Hughes K, Harris S, Shakir SA (2003a) Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology 42(11):1354–1364

Layton D, Heeley E, Hughes K, Shakir SA (2003b) Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42(11):1342–1353PubMedCrossRef

Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142(7):481–489PubMedCrossRef

Lindhardsen J, Gislason G, Jacobsen S, Ahlehoff O, Olsen A, Ole Rintek Madsen, Torp-Pedersen C, Hansen P (2013) Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 73(8):1515–1521

MacDonald TM, Wei L (2006) Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol 98(3):275–280PubMedCrossRef

Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM (2010a) Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 69(6):689–700PubMedCentralPubMedCrossRef

Mangoni AA, Woodman RJ, Gilbert AL, Knights KM (2010b) Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 19(5):490–498PubMed

McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13):1633–1644PubMedCrossRef

McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098PubMedCentralPubMedCrossRef

Moore N, Salvo F, Duong M, Blin P, Pariente A (2014) Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf 13(2):167–179PubMedCrossRef

Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A (2011) Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol 4(5):605–621PubMedCrossRef

Psaty BM, Weiss NS (2007) NSAID trials and the choice of comparators–questions of public health importance. N Engl J Med 356(4):328–330PubMedCrossRef

Ried K (2006) Interpreting and understanding meta-analysis graphs–a practical guide. Aust Fam Physician 35(8):635–638PubMed

Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M et al (2011) Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 89(6):855–866PubMedCrossRef

Salvo F, Antoniazzi S, Duong M, Molimard M, Bazin F, Fourrier-Reglat A et al (2014) Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf 13(5):573–585PubMedCrossRef

Sanaee F, Clements JD, Waugh AW, Fedorak RN, Lewanczuk R, Jamali F (2011) Drug-disease interaction: crohn’s disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol 72(5):787–797PubMedCentralPubMedCrossRef

Scheiman JM, Hindley CE (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32(4):667–677PubMedCrossRef

Schjerning Olsen AM, Fosbol EL, Gislason GH (2014) The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data. Basic Clin Pharmacol Toxicol 115(2):179–184PubMedCrossRef

Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 164(9):881–889PubMedCrossRef

Shi W, Wang YM, Li LS, Yan M, Li D, Chen NN et al (2004) Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study. Clin Drug Investig 24(2):89–101PubMedCrossRef

Singh G, Lanes S, Triadafilopoulos G (2004) Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 117(2):100–106PubMedCrossRef

Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086PubMedCentralPubMedCrossRef

Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G et al (2004) Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 44(7):777–784PubMedCrossRef

van Staa TP, Rietbrock S, Setakis E, Leufkens HG (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 264(5):481–492PubMedCrossRef

Varga Z, Kriska M, Kristova V, Petrova M (2013) Analysis of non-steroidal anti-inflammatory drug use in hospitalized patients and perception of their risk. Interdiscip Toxicol 6(3):141–144PubMedCentralPubMedCrossRef

Warner TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371(9608):270–273PubMedCrossRef

Whitehead A (2003) Meta-analysis of controlled clinical trials. Wiley, Chichester

Winkelmayer WC, Waikar SS, Mogun H, Solomon DH (2008) Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 121(12):1092–1098PubMedCrossRef

WHO-adverse reaction terminology (WHO-ART) (2009) Dictionary of pharmaceutical medicine, pp 192–193

World Health Organization (WHO) (2010) International statistical classification of diseases and related health problems 10th revision (ICD-10). World Health Organization, Geneva

Title: The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review
Authors: Waheed Asghar
Fakhreddin Jamali
Publication date: 01-02-2015
Publisher: Springer Basel
Published in: Inflammopharmacology / Issue 1/2015
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-014-0225-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Thermal spring water drinking attenuates dextran-sulfate-sodium-induced colitis in mice

Role of amplification in phospholipase Cγ2 activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori: effect of ghrelin

The potential of selected South African plants with anti-Klebsiella activity for the treatment and prevention of Ankylosing spondylitis

Dual inhibition of arachidonic acid pathway by mulberry leaf extract

Increased temperature and entropy production in cancer: the role of anti-inflammatory drugs

Modulation of PPARγ and TNFα by emu oil and glycyrrhizin in ulcerative colitis